Reason for request
Inclusion on the list of medicines reimbursed by National Insurance and approved for use by hospitals in the ‘Central neuropathic pain in adults’ indication extension.
Clinical Benefit
| Substantial |
The actual benefit of LYRICA in the treatment of central neuropathic pain in adults is substantial. |
Clinical Added Value
| no clinical added value |
Lyrica does not provide any improvement in actual benefit (IAB level V) over the usual management of central neuropathic pain in adults. |
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
0dhTvPxzAnk4BKmw
